5% Aciclovir or Honevo(Trademark) as a treatment for cold sores

Phase 3

Completed

• Conditions: Herpes Labialis; Skin - Dermatological conditions

• Registration Number: ACTRN12615000648527
• Lead Sponsor: Honeylab Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 950

Inclusion Criteria

Aged 16 years or over at the time of enrolment.
Presentation to a pharmacy for treatment of a cold sore.
First cold sore symptoms (including prodromal symptoms e.g. tingling/pain) within 72 hours.

Exclusion Criteria

Any participant who is pregnant or breastfeeding.
Known or suspected allergy to honey, bees, aciclovir and/or glycerin.
Any other condition which, at the investigators' discretion, it is believed may present a safety risk or impact the feasibility of the study or the study results.
Patient has used oral aciclovir or other antiviral medicine, or any topical treatment, medical or complementary, on the current sore.
Participants planning to take or use any concomitant medications, which in the opinion of the investigator, could affect the cold sore during the course of the trial. This includes any topical product, medical or complementary, on the cold sore, oral aciclovir or other antiviral medicine, oral complementary medicines for cold sores, such as lysine supplements.

Study & Design

• Study Type: Interventional
• Study Design: Not specified